Trial · NCT02183870
EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer
NCT02183870, Phase 2, Completed, University of Cologne
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer. Trials, record NCT02183870. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02183870
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer
- NCT number
- NCT02183870
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 34 participants, actual
- Lead sponsor
- University of Cologne
- Conditions
- Lung Cancer, Adenocarcinoma, NSCLC
- Interventions
- Crizotinib
- First posted
- 2014-07-08
- Last updated
- 2022-06-16
- Other registries' IDs
- eudract:2013-002737-38
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective Response Rate (ORR); evaluation criteria: investigator assessed RECIST v.1.1 analysis | From time of beginning of treatment until the documention of response according to RECIST v1.1 (expected average 12 months) . | CT/MRI scans will be performed to evaluate the efficacy of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 fusion genes (primary outcome measure: objective response rate (ORR) according to RECIST v.1.1) |
| Secondary | Progression Free Survival (PFS) according to RECIST v1.1; evaluation criteria: investigator assessed RECIST v.1.1 analysis | From time of beginning of treatment until the first documented event of progression according to RECIST v1.1 (expected average 12 months). | CT/MRI scans will be performed to assess the PFS during treatment period. |
| Secondary | Overall Survival (OS); evaluation criteria: investigator assessed RECIST v.1.1 analysis | From beginning to end of study (Last subject last visit (LSLV)) (up to approximately 24 months). | OS will be assessed by telephone calls every 3 months after the safety follow-up visit. |
| Secondary | Duration of Response (DR); evaluation criteria: investigator assessed RECIST v.1.1 analysis | From time of beginning of treatment until the documention of progression according to RECIST v1.1 (expected average 12 months). | CT/MRI scans will be performed to asses the DR. |
| Secondary | Time to Tumor Response; evaluation criteria: investigator assessed RECIST v.1.1 analysis | From time of beginning of treatment until the first documented event of response according to RECIST v1.1 (expected average 3 months). | CT/MRI scans will be performed to assess the Time to Tumor Response. |
| Secondary | Disease Control Rate (DCR); evaluation criteria: investigator assessed RECIST v.1.1 analysis | From beginning of treatment to week 6, 12 and 24 according to RECIST v1.1 (expected average 3 months). | CT/MRI scans will be performed at weeks 6, 12, 24 to assess the DCR. |
| Secondary | Safety/Adverse Events and tolerability in all patients treated with crizotinib assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram and RECIST1.1 | From beginning of treatment until 28 days post treatment (expected average 12 months). | Safety and tolerability will be assessed on every study visit and for 28 days after end of treatment. |
| Secondary | Patient Reported Outcomes (PRO) (EORTC QLQ-C30, EORTC QLQ-LC13) | Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30) completed at baseline and every 4 weeks from beginning of treatment until end of study. | Patient reported outcomes (PRO) of health-related quality of life (HRQoL), disease/treatment related symptoms of lung cancer and general health status |
| Secondary | To evaluate the efficacy of crizotinib treatment in the patient subgroup with ROS1 translocation confirmed by the CAGE technology regarding the objective response rate (ORR) (evaluation criteria: investigator assessed RECIST v1.1) | From time of beginning of treatment until the documention of response according to RECIST v1.1 (expected average 12 months) . | CT/MRI scans will be performed to evaluate the efficacy of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 fusion genes as confirmed by CAGE sequencing |
| Secondary | Objective Response Rate (ORR), Overall Survival (OS), Progression Free Survival (PFS), Duration of Response (DR), Time to Tumor Response, Disease Control Rate (DCR); evaluation criteria: RECIST v1.1 by independent radiologic review | From time of beginning of treatment until the documention of response according to RECIST v1.1 (expected average 12 months) . | CT/MRI scans will be performed to evaluate the efficacy of crizotinib treatment |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02183870
GET https://conductscience.org/api/trials/v1/NCT02183870/registered